drugset / Trial / NCT02449616

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616 ↗

Phase 3 Completed 16 enrolled Mast Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.

Timeline

Start
2015-06
Primary completion
2016-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Vepoloxamer Small molecule 30 mg/kg Intravenous

Indications